多组件,时间过程查,以开发基于协同毒性的组合癌症疗法
Michele Ceribelli1, Frances Anne Tosto1, Xiaohu Zhang1
1Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850.
概括
这项研究表明,体外药物查可以识别针对性癌症治疗的协同组合,如Venetoclax和Ibrutinib,用于淋巴瘤治疗. 这些组合有效诱导细胞亡和细胞死亡,反映了体内结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 癌症临床试验需要在疾病模型中强有力的机制逻辑和验证的药物活性.
- 现型查识别了药物活性,但缺乏优化多药疗法.
研究的目的:
- 评估体外药物查,以优化淋巴瘤中的多种药物组合.
- 在淋巴瘤细胞系中剖析Venetoclax,Ibrutinib,Prednisolone和Lenalidomide的活性.
主要方法:
- 使用四种小分子药物在淋巴瘤细胞系中进行体外查.
- 开发了一种用于同时暴露于多种药物的时间过程测试方法.
- 评估药物协同作用,亡和细胞毒性反应.
主要成果:
- 协同作用的药物组合在体内相关度下促进了细胞亡和细胞毒性.
- 快速,协同的亡诱导是多元组件向治疗活动的关键.
- 扩散大B细胞淋巴瘤模型显示药物对协同作用的异质性.
结论:
- 在体外药物查可以确定用于癌症治疗的协同作用的多药组合.
- 向治疗组合利用协同作用来克服瘤多样性.
- 化疗组合的益处有限,原因在于单个药物活性.
更多相关视频
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.9K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K